Related Experiment Video
Updated: Feb 16, 2026
07:40
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.7K
Anacetrapib as a potential cardioprotective strategy
Belinda A Di Bartolo1, Stephen J Nicholls1
1South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia.
Drug Design, Development and Therapy
|December 22, 2017
Summary
Cholesteryl ester transfer protein (CETP) inhibitors, like anacetrapib, show promise in cardiovascular prevention by altering cholesterol levels. Emerging evidence suggests anacetrapib may reduce cardiovascular events, warranting further clinical review.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Cholesteryl ester transfer protein (CETP) facilitates cholesterol transfer between lipoproteins.
- CETP inhibitors aim to increase HDL cholesterol and decrease LDL cholesterol for cardiovascular prevention.
- Previous CETP inhibitors faced challenges with clinical efficacy and safety.
Purpose of the Study:
- To review the development and clinical experience of anacetrapib, a potent CETP inhibitor.
- To evaluate the potential role of anacetrapib in reducing cardiovascular events.
- To discuss the clinical utility of anacetrapib in cardiovascular disease management.
Main Methods:
- Review of clinical studies and emerging evidence on anacetrapib.
- Analysis of anacetrapib's effects on lipid profiles (HDL-C, LDL-C).
- Evaluation of cardiovascular outcomes data associated with anacetrapib use.
Main Results:
- Anacetrapib has demonstrated potent inhibition of CETP activity.
- Emerging data suggest anacetrapib may reduce cardiovascular events.
- Anacetrapib's safety and efficacy profile is under continued investigation.
Conclusions:
- Anacetrapib represents a promising CETP inhibitor for cardiovascular prevention.
- Further clinical experience is needed to fully establish anacetrapib's role in practice.
- The potential benefits of anacetrapib in managing cardiovascular risk warrant consideration.
Related Concept Videos
01:26Atherosclerosis III: Management
459
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
459
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.3K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.3K
01:26Coronary Artery Disease IV: Preventive Measures
737
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
737
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
01:29Pharmacogenomics: Identification of New Drug Targets
9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9